Cidara Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Cidara Therapeutics has a total shareholder equity of $115.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $162.3M and $46.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$127.39m |
| Equity | US$115.63m |
| Total liabilities | US$46.70m |
| Total assets | US$162.33m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 20D0's short term assets ($156.8M) exceed its short term liabilities ($44.3M).
Long Term Liabilities: 20D0's short term assets ($156.8M) exceed its long term liabilities ($2.4M).
Debt to Equity History and Analysis
Debt Level: 20D0 is debt free.
Reducing Debt: 20D0 has no debt compared to 5 years ago when its debt to equity ratio was 20.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 20D0 has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: 20D0 is forecast to have sufficient cash runway for 12 months based on free cash flow estimates, but has since raised additional capital.